The slight difference in results is not clinically significant, and individual results vary based on adherence to diet and exercise recommendations
Recommended Timing and Dosing Schedule for Retatrutide Retatrutide is given as a once-weekly subcutaneous injection on a consistent chosen day, with dose escalation from a low starting dose up to 12 mg weekly as per trial protocol
A randomised controlled trial in 1,897 individuals living with type 2 diabetes compared the impact of three doses of tirzepatide (5mg, 10mg, and 15mg) compared to a once-weekly injection of 1mg semaglutide (Ozempic) on blood sugar levels
#Semaglutide #PharmaIndustry #PharmaMarketing #IndiaPharma #HealthcareTrends #FutureOfPharma #PharmaCareers #GLP1 To view or add a comment, sign in Indias GLP-1 Race Heats Up: Dr
Stable isotope tracing in vivo reveals a metabolic bridge linking the microbiota to host histone acetylation
Tirzepatide is a dual agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, while retatrutide is a triple agonist, targeting GIP, GLP-1, and GCG simultaneously
